Chinese medical company Asclepius Meditec reported on Monday the availability of an environmentally friendly treatment generator AMS-H-03 involving the electrolysis of H2O to produce a mixture of hydrogen and oxygen for inhalation by COVID-19 patients with no side effects.
In a multicentered, open-label clinical trial, titled "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial", the inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients. The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD).
Asclepius Meditec added that the research and clinical trial was conducted on 44 patients with COVID-19 whose dyspnea could not be ameliorated after regular treatment in 11 hospitals. After three days of continuous use of the hydrogen/oxygen generator, AMS-H-03 , all 44 patients showed significant improvement compared with 46 patients who received the standard regimen of oxygen alone.
According to the company, the hydrogen/oxygen generator AMS-H-03 has received the Class III Medical Device certificate from China's National Medical Products Administration. The AMS-H-03 helps to reduce the mortality rate associated with COVID-19.
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD